The Chinese government is restricting American investment in its artificial intelligence sector to safeguard national security by limiting U. S. access to sensitive technologies. This situation highlights the need for the U. S. to also protect its critical sectors, especially healthcare.
• About 131 million Americans rely on prescription medications, yet the U. S. pharmaceutical supply chains are heavily reliant on foreign nations, mainly China.
• China produces a significant share of Active Pharmaceutical Ingredients (APIs), which are essential for many medications, creating a vulnerability for the U. S. during crises.
• China's previous actions, such as leveraging rare earth minerals in trade disputes, show its willingness to use supply chains as a weapon.
• China's national development plans target strategic industries, including biotechnology, posing a threat to U. S. medical advancements.
• The U. S. can counter this reliance through free market capitalism, supported by tax reforms and pro-business initiatives to boost domestic pharmaceutical manufacturing.
• Investments in areas like Indiana, North Carolina, and Puerto Rico showcase the potential to enhance “Made in America” drug production.
Securing America’s healthcare supply chains from foreign disruption is crucial for national security, as echoed by Congressman Nathaniel Moran's statement about the dependency on Beijing.
No comments:
Post a Comment